Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Polarean Imaging ( (GB:POLX) ) has shared an announcement.
Polarean Imaging announced that Dr. Bastiaan Driehuys, its Chief Scientific Officer, received the 2025 American Thoracic Society Respiratory Health Award for his pioneering work in Xenon MRI technology. This recognition highlights the impact of Dr. Driehuys’ contributions to pulmonary imaging, which have advanced the science and improved patient outcomes by enabling earlier detection and better treatment planning for respiratory conditions.
The most recent analyst rating on (GB:POLX) stock is a Buy with a £8.00 price target. To see the full list of analyst forecasts on Polarean Imaging stock, see the GB:POLX Stock Forecast page.
More about Polarean Imaging
Polarean Imaging is a medical imaging technology company focused on revolutionizing pulmonary medicine by providing advanced MRI solutions for lung function visualization. The company has developed the first FDA-approved hyperpolarized Xenon MRI inhaled contrast agent, XENOVIEW®, and is committed to addressing global unmet medical needs in respiratory healthcare.
Average Trading Volume: 2,574,230
Technical Sentiment Signal: Sell
Current Market Cap: £14.48M
For an in-depth examination of POLX stock, go to TipRanks’ Stock Analysis page.